Strs Ohio Takes Position in Liquidia Co. (NASDAQ:LQDA)

Strs Ohio bought a new stake in Liquidia Co. (NASDAQ:LQDA – Get Rating) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,600 shares of the company’s stock, valued at approximately $63,000.

Several other hedge funds also recently modified their holdings of the business. State Street Corp boosted its stake in Liquidia by 861.0% during the 2nd quarter. State Street Corp now owns 1,448,211 shares of the company’s stock worth $6,314,000 after acquiring an additional 1,297,509 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in Liquidia during the 2nd quarter worth approximately $1,923,000. Opaleye Management Inc. boosted its stake in Liquidia by 191.7% during the 2nd quarter. Opaleye Management Inc. now owns 521,500 shares of the company’s stock worth $2,274,000 after acquiring an additional 342,700 shares during the last quarter. Northern Trust Corp boosted its stake in Liquidia by 468.4% during the 2nd quarter. Northern Trust Corp now owns 408,701 shares of the company’s stock worth $1,782,000 after acquiring an additional 336,794 shares during the last quarter. Finally, Invesco Ltd. bought a new position in Liquidia during the 1st quarter worth approximately $1,850,000. Institutional investors own 32.64% of the company’s stock.

Liquidia Stock Performance

Shares of LQDA opened at $6.42 on Friday. The firm’s 50 day moving average price is $5.76 and its two-hundred day moving average price is $5.59. The firm has a market cap of $414.06 million, a P/E ratio of -7.83 and a beta of 0.13. Liquidia Co. has a twelve month low of $3.26 and a twelve month high of $8.79.

Liquidia (NASDAQ:LQDA – Get Rating) last announced its quarterly earnings data on Tuesday, November 8th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $3.17 million during the quarter, compared to the consensus estimate of $3.50 million. On average, sell-side analysts anticipate that Liquidia Co. will post -0.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Wedbush reissued an “underperform” rating and set a $3.00 price objective on shares of Liquidia in a research note on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.67.

Liquidia Profile

(Get Rating)

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.